HK Stock Market Move | PEIJIA-B(09996) rose nearly 6% in early trading. Recently, it signed an exclusive distribution agreement with B. Braun Medical for SeQuent Please CIS.

PEIJIA-B (09996) rose nearly 6% in early trading, rising 2.23% to HK$4.12 as of press time, with a transaction volume of HK$4.0149 million. On the news front, Peijia Medical recently announced that its subsidiary Jachie Biotech has entered into an exclusive distribution agreement with B. Medical. According to the agreement, Jachie Biotech has obtained exclusive distribution rights for B. Medical's product SeQuent Please CIS Paclitaxel-coated Intracranial Balloon Dilatation Catheter (SeQuent Please CIS) in mainland China. The cooperation with B. Medical further enriches the group's portfolio of neurointerventional products and strengthens the group's strategic layout in the field of innovative intracranial intervention solutions. China Securities Co., Ltd. previously stated that with the commercialization and ramp-up of the company's TaurusTrio reflux valve, as well as the expected market approval of several heavyweight innovative products such as the third-generation TAVR product TaurusNXT and the mitral valve edge-to-edge repair reflux product GeminiOne within 2026, the company's product portfolio in the field of structural heart disease continues to enrich, and its technological leadership and long-term competitiveness will be further consolidated.